Evaluation of the efficacy of a live Escherichia coli biotherapeutic product (asymptomatic bacteriuria E. coli 212)
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2024. Verfasst von Gilad Segev und 7 weiteren Autor:innen. Beteiligte Einrichtung: Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Dog Diseases, Escherichia coli, Bacteriuria, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Morris Animal Foundation.
Abstract (Originalsprache)
Background
Recurrent bacterial cystitis, often referred to as recurrent urinary tract infection (UTI), can be difficult to manage and alternative treatments are needed. Hypothesis/Objective Intravesicular administration of asymptomatic bacteriuria (ASB) E. coli 212 will not be inferior to antimicrobial treatment for the management of recurrent UTI in dogs. Animals Thirty-four dogs with >1 UTI in the 12 months before presentation.
Methods
All dogs were deemed normal otherwise based on absence of abnormalities on physical examination, CBC, serum biochemical panel, and abdominal ultrasonography. Dogs were randomized to 1 of 2 treatment groups: Group 1 antimicrobials for 7 days or group 2 intravesicular administration of ASB E. coli 212. Owners were provided a voiding questionnaire regarding their dogs' clinical signs, which was completed daily for 14 days to assess clinical cure. Dogs were examined on days 7 and 14 to assess clinical cure, and urine specimens were submitted for urinalysis and bacterial culture.
Results
Clinical cure rates for ASB E. coli 212–treated dogs were not inferior to 7 days of antimicrobial treatment with a 12% margin of difference to determine non-inferiority. No significant difference was found between the treatment groups on days 7 and 14 in the proportion of dogs achieving ≥50% or ≥75% reduction in their clinical score compared with baseline. Conclusions and Clinical Importance These data suggest that intravesicular administration of ASB E. coli 212 is not inferior to antimicrobials for the treatment of recurrent UTI in dogs. This biotherapeutic agent could help alleviate the need for antimicrobials for some dogs with recurrent UTI, improving antimicrobial stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.
- Veterinary Center for Clinical Trials, University of California, Davis, Davis, California, USA.
- Department of Urology, Feinberg School of Medicine, Northwestern University, Evanston, Illinois, USA.
ORCID-Profile: Gilad Segev, Hilla Chen, Jonathan D Dear, Jodi L Westropp
Förderung
- Morris Animal Foundation
Zitieren
APA
Segev, G., Chen, H., Dear, J. D., Martínez López, B., Pires, J., Klumpp, D. J., Schaeffer, A. J., & Westropp, J. L. (2024). Evaluation of the efficacy of a live Escherichia coli biotherapeutic product (asymptomatic bacteriuria E. coli 212). Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17167
Vancouver
Segev G, Chen H, Dear JD, Martínez López B, Pires J, Klumpp DJ, et al. Evaluation of the efficacy of a live Escherichia coli biotherapeutic product (asymptomatic bacteriuria E. coli 212). Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17167
BibTeX
@article{Segev2024,
author = {Segev, Gilad and Chen, Hilla and Dear, Jonathan D and Martínez López, Beatriz and Pires, Jully and Klumpp, David J and Schaeffer, Anthony J and Westropp, Jodi L},
title = {Evaluation of the efficacy of a live Escherichia coli biotherapeutic product (asymptomatic bacteriuria E. coli 212)},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17167}
}
EUVIMED